Status:

UNKNOWN

Effect of Dapagliflozin in Non-Diabetic Patients With Nephrotic Syndrome.

Lead Sponsor:

Ain Shams University

Conditions:

Nephrotic Syndrome

Eligibility:

All Genders

18-60 years

Phase:

PHASE4

Brief Summary

Dapagliflozin is the first SGLT2 inhibitor to be approved for CKD treatment regardless of diabetes status. Since many etiologies of non-diabetic nephropathy are characterized by intraglomerular hypert...

Detailed Description

Nephrotic syndrome (NS) is a clinical syndrome defined by massive proteinuria (greater than 40 mg/m2 per hour) responsible for hypoalbuminemia (less than 30 g/L), with resulting hyperlipidemia, edema,...

Eligibility Criteria

Inclusion

  • Age ≥18 and ≤60 years.
  • Patients with diagnosis of nephrotic syndrome (proteinuria ≥3.5g/24hr, and serum albumin ≤30g/L) and Urine protein/Creatinine Ratio (UPCR) ≥2.
  • Serum creatinine \<3mg/dl (265.2umol/L) and eGFR \>30 ml/min/1.73 m2.
  • Pathological diagnosis with membranous nephropathy (MN) or focal segmental glomerulosclerosis (FSGS).
  • Absence of any contraindication to dapagliflozin (eGFR less than 30).
  • On a stable dose of an ACEI or ARB for at least 4 weeks prior to randomization or Initiation of ACEI or ARB.
  • Agreed to participate and sign written informed consent.

Exclusion

  • Diagnosis of type 1 or type 2 diabetes mellitus.
  • Autosomal dominant polycystic kidney disease or autosomal recessive polycystic kidney disease or lupus nephritis.
  • Active malignancy aside from treated squamous cell or basal cell carcinoma of the skin.
  • History of severe hypersensitivity or contraindications to dapagliflozin.
  • History of repeated urinary tract infection or fungal infection.
  • Patients with Hemodynamic instability or Hypotension.
  • History of noncompliance to medical regimens or unwillingness to comply with the study protocol.
  • Pregnancy or breastfeeding.

Key Trial Info

Start Date :

August 1 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 1 2024

Estimated Enrollment :

90 Patients enrolled

Trial Details

Trial ID

NCT05966818

Start Date

August 1 2023

End Date

March 1 2024

Last Update

August 1 2023

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.